Landos (LABP) Secures AbbVie Deal: Propelling Novel Oral Therapy Development
Landos (LABP) Secures AbbVie Deal: Propelling Novel Oral Therapy Development
The current surge of Landos Biopharma, Inc. (NASDAQ: LABP) shares on the US charts, marking a notable surge of 168.27% to $21.46 per share as of the last check, is attributed to a takeover bid.
Landos Biopharma, Inc.（纳斯达克股票代码：LABP）目前在美国排行榜上的股价飙升，截至上次支票时每股大幅上涨168.27％，至21.46美元，这归因于收购要约。
Today, Landos (LABP) disclosed a definitive agreement with AbbVie Inc., outlining AbbVie's intent to acquire Landos. At the forefront of Landos' offerings is NX-13, a pioneering oral NLRX1 agonist boasting a bimodal mechanism of action (MOA), renowned for its anti-inflammatory properties and its facilitation of epithelial repair.
今天，兰多斯（LABP）披露了与艾伯维公司达成的最终协议，概述了艾伯维收购兰多斯的意图。Landos 产品的前沿是 NX-13，这是一种开创性的口服 NLRX1 激动剂，具有双模态作用机制 (MOA)，以其抗炎特性和促进上皮修复而闻名。
The acquisition underscores AbbVie's strategic pursuit to propel the clinical progression of NX-13, distinguished for its innovative oral formulation and its potential to ameliorate the conditions of individuals grappling with ulcerative colitis and Crohn's disease.
此次收购凸显了艾伯维推动 NX-13 临床进展的战略追求。以其创新的口服配方及其改善溃疡性结肠炎和克罗恩病患者病情的潜力而著称。
This announcement epitomizes Landos' steadfast dedication to its mission of developing oral therapeutics tailored to fill existing treatment voids. NX-13, along with its bimodal MOA, presents a promising avenue for addressing the complexities of ulcerative colitis and Crohn's disease.
该公告体现了Landos坚定不移地致力于开发量身定制的口服疗法以填补现有治疗空白的使命。NX-13 及其双模式 MOA 为解决溃疡性结肠炎和克罗恩氏病的复杂性提供了一个有希望的途径。
Given AbbVie's proficiency in therapeutic domains and its global development acumen, the company is poised to advance NX-13 effectively. NLRX1 serves as a pivotal regulator of immunometabolism and inflammation, with its activation influencing various facets of inflammatory bowel disease (IBD) pathogenesis.
鉴于艾伯维在治疗领域的熟练程度及其全球开发敏锐度，该公司准备有效推进 NX-13。NLRX1 是免疫代谢和炎症的关键调节剂，其激活会影响炎症性肠病 (IBD) 发病机制的各个方面。
Currently, the randomized controlled Phase 2 NEXUS clinical trial evaluating NX-13 in ulcerative colitis is actively enrolling patients across the United States and Europe (NCT05785715). Per the terms delineated in the agreement, AbbVie is set to acquire Landos at a per-share price of $20.42 in cash upon closure, totaling approximately $137.5 million.
目前，评估 NX-13 治疗溃疡性结肠炎的随机对照 2 期 NEXUS 临床试验正在积极招收美国和欧洲各地的患者（NCT05785715）。根据协议中规定的条款，艾伯维将在收盘时以每股20.42美元的现金价格收购兰多斯，总额约为1.375亿美元。
Additionally, the deal incorporates a non-tradable contingent value right per share, valued at up to $11.14, amounting to an additional approximately $75 million contingent upon the attainment of a clinical development milestone. The anticipated finalization of the transaction is slated for the second quarter of 2024, pending customary closing prerequisites, including approval from Landos' shareholders.
此外，该交易还包括每股不可交易的或有价值权，价值最高为11.14美元，总额约为7,500万美元，视临床开发里程碑的实现而定。该交易预计将于2024年第二季度完成，尚待包括Landos股东批准在内的惯例成交先决条件。
译文内容由第三方软件翻译。